
Agilon Health (AGL) Stock Forecast & Price Target
Agilon Health (AGL) Analyst Ratings
Bulls say
Agilon Health Inc. demonstrated impressive financial performance in the fourth quarter, with total revenue increasing by 44.2% year-over-year, slightly exceeding expectations. The company's membership in Medicare Advantage (MA) grew by 36% year-over-year, reaching 527,000 members, bolstered by steady growth in existing geographies. Additionally, improvements in medical cost tracking and lower-than-anticipated operating expenses suggest a positive trajectory for managing operating efficiency and costs, enhancing the overall outlook for the company's financial health.
Bears say
Agilon Health has faced significant visibility issues concerning utilization forecasting, leading to a negative surprise in financial results for the latter half of 2023, particularly with a reported adjusted EBITDA of $(84.0) million, which was below prior estimates due to lower medical margins. The company's guidance for ACO REACH patients indicates a substantial quarter-over-quarter decline, which raises concerns about future earnings potential, with expected contributions to EBITDA in 2025 aligning closely with previous years despite potential headwinds from exiting an unprofitable partnership. Additionally, Agilon's trading metrics reflect a concerning valuation at 0.2 times projected 2025 revenue, significantly lower than its peers, indicating investor apprehension regarding its financial stability and growth trajectory.
This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares